Q32 Bio Inc. — Form 8-K
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Q32 Bio announced 36-week topline results from SIGNAL-AA Part B, a Phase 2a trial of bempikibart (IL-7Rα antagonist) in severe/very severe alopecia areata. In the modified intent-to-treat population (n=25), bempikibart achieved 35.3% mean SALT score reduction, with 40.0% of patients achieving SALT-20 response; 30.3% SALT-20 response in full ITT (n=33). Safety profile was favorable with no Grade 3+ adverse events, negligible anti-drug antibodies, and predominantly mild injection site reactions (4% incidence). Company plans registration-directed program initiation in H1 2027.
Why this rating
Clinical proof-of-concept in promising indication with favorable safety supports advancement toward registration. At $10.4M market cap, successful Phase 2 progression materially reduces clinical risk and could enable value inflection via partnership or funding.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.